OptiNose, Inc. (OPTN)

NASDAQ: OPTN · Real-Time Price · USD
9.15
+0.01 (0.11%)
At close: Mar 28, 2025, 4:00 PM
9.10
-0.05 (-0.55%)
After-hours: Mar 28, 2025, 7:52 PM EDT
0.11%
Market Cap 92.01M
Revenue (ttm) 78.23M
Net Income (ttm) -21.54M
Shares Out 10.06M
EPS (ttm) -2.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 93,271
Open 9.15
Previous Close 9.14
Day's Range 9.13 - 9.17
52-Week Range 4.82 - 22.35
Beta -0.31
Analysts Hold
Price Target 9.00 (-1.64%)
Earnings Date Mar 26, 2025

About OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a l... [Read more]

Sector Healthcare
IPO Date Oct 13, 2017
Employees 132
Stock Exchange NASDAQ
Ticker Symbol OPTN
Full Company Profile

Financial Performance

In 2024, OptiNose's revenue was $78.23 million, an increase of 10.20% compared to the previous year's $70.99 million. Losses were -$21.54 million, -39.29% less than in 2023.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for OPTN stock is "Hold." The 12-month stock price forecast is $9.0, which is a decrease of -1.64% from the latest price.

Price Target
$9.0
(-1.64% downside)
Analyst Consensus: Hold
Stock Forecasts

News

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of OptiN...

7 days ago - Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders

NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or brea...

Other symbols: BECN
7 days ago - GlobeNewsWire

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...

9 days ago - GlobeNewsWire

Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10 ‑ million ‑ patient market Acquisition advances Paratek's ...

9 days ago - GlobeNewsWire

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million

Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% Preliminary XHANCE prescription growth rate from third quarter to fourth quarter...

2 months ago - GlobeNewsWire

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announc...

3 months ago - GlobeNewsWire

Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference

YARDLEY, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

4 months ago - GlobeNewsWire

OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript

OptiNose, Inc. (NASDAQ:OPTN) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jonathan Neely - Vice President of Investor Relations and Business Development Ramy Mah...

4 months ago - Seeking Alpha

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights

Company reports Q3 2024 XHANCE net revenue of $20.4 million , an increase of 3% compared to Q3 2023

4 months ago - GlobeNewsWire

Optinose Announces Reporting Date for Third Quarter 2024 Financial Results

Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time

5 months ago - GlobeNewsWire

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

YARDLEY, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announce...

5 months ago - GlobeNewsWire

Optinose Appoints Terry Kohler as Chief Financial Officer

YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...

6 months ago - GlobeNewsWire

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery

YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...

7 months ago - GlobeNewsWire

Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference

YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

7 months ago - GlobeNewsWire

OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript

OptiNose, Inc. (NASDAQ:OPTN) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Paul Spence - Chief C...

8 months ago - Seeking Alpha

Optinose Announces Reporting Date for Second Quarter 2024 Financial Results

Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time

8 months ago - GlobeNewsWire

Expanded Access to XHANCE with Addition to National Commercial Formularies

YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

9 months ago - GlobeNewsWire

OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript

OptiNose, Inc. (NASDAQ:OPTN) Q1 2024 Results Conference Call May 15, 2024 10:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Conference Call Partic...

11 months ago - Seeking Alpha

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that ...

11 months ago - GlobeNewsWire

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights

Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million Company expe...

11 months ago - GlobeNewsWire

Optinose Announces Reporting Date for First Quarter 2024 Financial Results

Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time

11 months ago - GlobeNewsWire

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million

Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time

1 year ago - GlobeNewsWire

Optinose to Present at the Needham Virtual Healthcare Conference

YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced tha...

1 year ago - GlobeNewsWire

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

ReOpen was th e first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps

1 year ago - GlobeNewsWire

OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript

OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Conference Call March 7, 2024 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Ramy Mahmoud - CEO Conference Call Participa...

1 year ago - Seeking Alpha